Mineralys Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 |
|---|---|---|---|---|
| Operating income | -$170.6M | -$192.4M | -$84.7M | -$31.5M |
| Operating expenses | $170.6M | $192.4M | $84.7M | $31.5M |
| Cash from operations | -$142.4M | -$166.3M | -$81.2M | -$29.2M |
| Capital expenditure | $15,000 | $96,000 | $0 | — |
| Free cash flow | -$142.4M | -$166.4M | -$81.2M | — |
| Total assets | $661.8M | $205.9M | $251.6M | $114.4M |
Shares outstanding 82.5M · Free float 73.9%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.